TRT and Swelling and Water Retention: Causes and What to Do

Water retention is one of the adverse effects of testosterone therapy that appears in product information, on forums and in doctors' offices — although it is rarely the main topic of conversations about TRT. Men describe it in different ways: as 'puffiness' after taking off socks, tight rings, a feeling of heavy legs in the evening, a bloated abdomen, or a sudden weight rise of a few kilograms in the first weeks. Not all of these symptoms mean the same thing, and their causes and clinical significance differ fundamentally.

In this article we organize the topic in three steps. First, we check what studies have actually shown about testosterone's effect on fluid balance. Next, we tell true edema from phenomena that mimic it. Finally, we identify who is most affected, what to test and when the symptom becomes a warning sign.

The question of whether testosterone retains water seems trivial, and for years the answer relied on clinical observations and adverse events from trials with a different aim. It was measured directly in a small but carefully planned randomized study that assessed the volume of extracellular water.

What follows from this? First, this is one of the few studies that measured extracellular water directly, and it shows that testosterone increases it in men with hypogonadism — so the effect is real, not just 'forum lore'. Second, the study was small (12 people), open-label (not blinded) and carried out in a very specific population with hypopituitarism, so the figures cannot be transferred directly to every man on TRT. Third, the study does not answer how often fluid retention leads to clinically visible edema — it measured volume, not edema as a symptom.

For comparison, in large randomized trials and reviews of TRT, edema is listed as a possible adverse effect within a broader set of events but is rarely their main subject, and there is no reliable figure for its incidence in the general population of men treated with testosterone. Product information usually lists edema as a possible effect, without precise values.

A popular explanation holds that androgens retain sodium and water by stimulating the renin–angiotensin–aldosterone system (RAAS), as some corticosteroids do. This reasoning sounds intuitive, but the study by Johannsson et al. does not confirm it: in the men in whom testosterone increased ECW, plasma renin activity did not change and aldosterone fell. In other words, fluid retention occurred despite no activation of the RAAS axis, which suggests a different point of action.

The authors point to a direct effect on the renal tubules as the probable explanation — that is, increased reabsorption of sodium (and water with it) in the nephron independent of aldosterone. The molecular details go beyond what the study proved, so on this matter it is right to speak of a hypothesis. The important practical conclusion is that in a man with edema on TRT one should not assume in advance that 'it's aldosterone' and reach for drugs that block its receptor; decisions about diuretic treatment should be made by a doctor after assessing the cause.

In the TRT community water retention is almost automatically linked to estradiol: testosterone is aromatized in tissues to estradiol, and an excess of it is associated with fluid retention, breast tenderness, irritability and 'bloating'. There is a grain of truth in this belief, but also a considerable simplification. Estradiol does affect sodium balance, and in some men on TRT its concentration rises. However, the study with growth hormone and testosterone shows that testosterone alone increases extracellular water; it does not prove that it does so solely through estradiol, nor that estradiol plays no part.

Practically, this means two things. First, symptoms 'from estradiol' and 'from testosterone' are hard to separate clinically, so attributing them without a test result is guesswork. Second, a sensible assessment includes measuring estradiol in the blood at the right point of the injection cycle, but the result must be interpreted together with symptoms and other parameters, not treated as 'a number to lower'. We write about estradiol on TRT in more detail in our entries on estradiol and on its level during therapy.

Not every 'water retention' is edema. The distinction matters because different phenomena require different handling. True edema is an excess of fluid in the interstitial space; it is most often visible as a dent after pressing with a finger ('pitting' edema) above the ankles, on the feet and shins, and in advanced edema also in the lower back, hands or face. It is usually bilateral and symmetrical, worsens toward the end of the day and may be smaller in the morning.

A good tool is daily weighing in the morning after urinating, on the same scale. Rapid weight changes of 1–2 kg over a few days usually reflect fluid and not tissue, because fat or muscle gain is slower. Also record calf circumference at the same height and compare it after a few days. Such data help the doctor tell transient retention from a growing problem.

In most healthy men, water retention on TRT is mild, transient and needs only observation. The situation is different for people whose body has a limited ability to remove excess sodium and fluid. This applies above all to heart failure, chronic kidney disease, nephrotic syndrome, liver cirrhosis and severe venous insufficiency. In these conditions additional fluid retention can worsen breathlessness, edema and the load on the organ, which is why starting TRT requires agreement with a cardiologist, nephrologist or hepatologist.

Factors that can worsen fluid retention in a man on TRT also include: high salt intake and processed food, nonsteroidal anti-inflammatory drugs, some antihypertensives (e.g. amlodipine), corticosteroids, glitazones, growth hormone and prolonged immobilization. Remember blood pressure, too: in February 2025 the US drug regulator updated the labeling of testosterone products, removing the boxed warning on major cardiovascular events and adding a class-wide warning on possible increases in blood pressure, based on ambulatory measurements. In the context of edema this means that blood pressure control is part of the assessment — we write more about it in our entry on TRT and blood pressure.

Assessing edema does not come down to measuring testosterone. The doctor usually starts with a history (when it appeared, whether it is one-sided, whether shortness of breath accompanies it, whether urine volume has changed), a physical examination (pulse, blood pressure, listening to the heart and lungs, assessing the jugular veins, assessing pitting) and basic laboratory tests. A sensible set includes a blood count with hematocrit, creatinine with eGFR, electrolytes (sodium, potassium), albumin, liver tests, urinalysis with an assessment of proteinuria and TSH, and if heart failure is suspected — natriuretic peptide (NT-proBNP) and echocardiography. On TRT also testosterone, estradiol and SHBG at a fixed point of the cycle.

Electrolytes and kidney parameters are worth interpreting in context rather than in isolation; our entries on electrolytes (sodium, potassium, chlorides) and on creatinine are useful. If deep vein thrombosis is suspected, urgent diagnostics are needed (vein ultrasound, possibly D-dimer), not observation at home. We discuss the details of thrombosis in the article on TRT and the risk of venous thrombosis.

Remember the limits of the available data. Fluid retention on TRT is described in the literature mainly as a side phenomenon; there are no large trials that measured edema as the primary endpoint, and it is hard to give a reliable percentage of men who experience it. The only direct measurements come from a small study in a specific population. Decisions about management should therefore rest on individual assessment, not generalizations.

Water retention on TRT is a real phenomenon, but most often mild, transient and manageable by simple means. The most important thing is not to fall into two extremes: dismissing it in people with heart, kidney or liver disease, and automatically blaming estradiol and reaching for drugs without assessing the cause. A careful history, blood pressure measurement, a few basic tests and knowledge of the warning signs are usually enough to get safely through this stage of therapy.